Optimizing use of GLP-1 receptor agonists: safety, tolerability, adherence, and patient selection in cardiovascular practice
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have fundamentally transformed modern cardiometabolic care, moving beyond glycemic control to become a cornerstone of obesity management and potent cardiovascular risk reduction. Large-scale clinical trials consistently highlight their cardioprotective benefits, demonstrating significant reductions in major adverse cardiovascular events (MACE), cardiovascular mortality, and obesity-related heart failure complications. However, translating these remarkable clinical trial successes into routine clinical practice reveals a marked gap between efficacy and effectiveness, primarily driven by suboptimal patient persistence and adherence. This narrative review synthesizes current evidence regarding the pharmacology, safety, tolerability, adherence, and patient selection of GLP-1RAs to support optimal therapeutic decision-making in cardiovascular practice. While long-term data disprove clear causal relationships with pancreatic or thyroid malignancies, a high incidence of predictable, dose-related gastrointestinal adverse events (nausea, vomiting, diarrhea) remains the leading cause of early treatment discontinuation. Additionally, treatment persistence in clinical practice is heavily influenced by financial burdens, supply chain instability, and formulation choices. Cardioprotective benefits are well-established for patients with type 2 diabetes and atherosclerotic cardiovascular disease. Mitigating challenges in clinical practice requires a systematic, multi-step prescribing framework focused on targeted patient selection, gradual individualized dose titration ("start low and go slow"), and proactive multidisciplinary symptom management.
Authors
- Ana V. Pejčić (ORCID: https://orcid.org/0000-0003-1741-0025)
- Miloš N. Milosavljević (ORCID: https://orcid.org/0000-0002-1786-1507)
- Srđjan Stefanović (ORCID: https://orcid.org/0000-0003-2206-2037)
Institutions
- University of Kragujevac (RS)
- Clinical Centre of Kragujevac (RS)
Publication Details
- Journal
- Journal of Cardiovascular Pharmacology
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1097/fjc.0000000000001901
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00